<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OCTREOTIDE ACETATE</span><br/>(oc-tre'o-tide)<br/><span class="topboxtradename">Sandostatin, </span><span class="topboxtradename">Sandostatin LAR depot<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">antidiarrheal</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.05 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.5 mg/mL, 1 mg/mL injection; 10 mg/5 mL, 20 mg/5 mL, 30 mg/5 mL depot injection</p>
<h1><a name="action">Actions</a></h1>
<p>A long-acting peptide that mimics the natural hormone somatostatin. Suppresses secretion of serotonin, pancreatic peptides,
         gastrin, vasoactive intestinal peptide, insulin, glucagon, secretin, and motilin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Stimulates fluid and electrolyte absorption from the GI tract, prolongs intestinal transit time, and also inhibits the growth
         hormone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. Also watery diarrhea
         associated with vasoactive intestinal peptide (VIP) tumors.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acromegaly associated with pituitary tumors, fistula drainage, variceal bleeding.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to octreotide.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cholelithiasis, renal impairment; pregnancy (category B); diabetes, and hypothyroidism. It is not known whether drug is excreted
         in breast milk.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Carcinoid Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 100600 mcg/d in 24 divided doses, titrate to response <span class="rdroute">IM</span> May switch to depot injection after 2 wk at 20 mg q4wk times 2 mo<br/><span class="rdage">Child:</span> <span class="rdroute">SC</span> 110 mcg/kg/d in 24 divided doses, titrate to response<br/><br/><span class="indicationtitle">VIPoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 200300 mcg/d in 24 divided doses, titrate to response <span class="rdroute">IM</span> May switch to depot injection after 2 wk at 20 mg q4wk times 2 mo<br/><span class="rdage">Child:</span> <span class="rdroute">SC</span> 110 mcg/kg/d in 24 divided doses, titrate to response<br/><br/><span class="indicationtitle">Acromegaly</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 50 mcg t.i.d., titrate up to 100 mcg500 mcg t.i.d. <span class="rdroute">IM</span> May switch to depot injection after 2 wk at 20 mg q4wk times at least 3 mo, then reassess<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>
            				Note: Subcutaneous is the preferred route.
            			
         </li>
<li>Minimize GI side effects by giving injections between meals and at bedtime.</li>
<li>Avoid multiple injections into the same site. Rotate SC sites on abdomen, hip, and thigh.</li>
<li>Give deep IM into a large muscle. To reduce local irritation, allow solution to reach room temperature before injection and
            administer slowly.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">Intermittent:</span> Dilute in 50200 mL D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 3 min. In carcinoid give rapid IV bolus over 60 sec.  <span class="methodtype">Intermittent:</span> Give over 1530 min.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, fatigue, dizziness. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea,</span> abdominal pain and discomfort. <span class="typehead">Metabolic:</span> Hypoglycemia, hyperglycemia, increased liver transaminases, hypothyroidism (after long-term use). <span class="typehead">Body as a Whole:</span> Flushing, edema, injection site pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease <b>cyclosporine</b> levels; may alter other drug and nutrient absorption because of alterations in GI motility. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from SC injection site. <span class="typehead">Peak:</span> 0.4 h. <span class="typehead">Duration:</span> Up to 12 h. <span class="typehead">Metabolism:</span> 68% metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodic blood glucose, liver function tests, and serum electrolytes.</li>
<li>Monitor for hypoglycemia and hyperglycemia (see Appendix F), because octreotide may alter the balance between insulin, glucagon,
            and growth hormone.
         </li>
<li>Monitor fluid and electrolyte balance, as octreotide stimulates fluid and electrolyte absorption from GI tract.</li>
<li>Dietary fat absorption may be altered in some clients. Monitor fecal fat and serum carotene to aid in the assessment of possible
            drug-induced aggravation of fat malabsorption.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn proper technique for SC injection if self-medication is required.</li>
<li>
            							Note: Preferred sites for SC injections of octreotide are the hip, thigh, and abdomen. Multiple injections at the same SC injection
            site within short periods of time are not recommended. This is to avoid irritating the area.
            						
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>